Bio Special Special Report

The Netherlands Positions Itself as Europe’s Gateway for Life Sciences Innovation

For biotechnology companies looking towards Europe, the opportunity is considerable—but so is the complexity. Accessing one of the world’s larg...

 July 20, 2026 | News

Hong Kong Makes Its Case as Asia’s Biotech Super-Connector: Capital, Regulation and Scale Converge

  Hong Kong is seeking to redefine its place in the global life sciences economy. No longer content to be viewed primarily as a financial gateway int...

 July 20, 2026 | News

Australia and Taiwan Build a Faster Clinical Bridge for Global Biotech Development

  As biotechnology companies face mounting pressure to move promising science into human studies faster, the relationship between Australia and Taiwa...

 July 20, 2026 | News

Neurizon Completes Rapid Phase II/III NUZ-001 Enrolment for ALS with Results Expected in Q2 2027

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY AL...

 July 20, 2026 | News

Two Chairs, 11,000 Kilometres Apart: The Human Cost of Asia’s Plasma Dependence

REPORTAGE  /  PLASMA SUPPLY THE CHAIR The chair reclines. That is the first thing you notice, walking into a plasma centre in a strip mall on...

 July 17, 2026 | Analysis

China Plus One: Slogan, Strategy, or Capacity APAC Does Not Have?

THE RESHUFFLE      ·   ANALYSIS On a Monday in June 2026, one line in the United States Federal Register did what two year...

 July 16, 2026 | Analysis

The Technology Is Ready. Are APAC’s Regulators?

In a process-development suite in Singapore, or Hyderabad, or Songdo, a perfusion bioreactor can now run for weeks, its output feeding straight into a conn...

 July 15, 2026 | Regulatory

Q32 Bio Reports Positive Phase 2a Results for Bempikibart in Severe Alopecia Areata, Plans Pivotal Programme

-- Clinically meaningful efficacy data on the primary endpoint was observed with a mean percent reduction in SALT score from baseline o...

 July 15, 2026 | News

The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.

A control room that thinks it knows what happens next Walk the mezzanine above a modern biologics suite in Singapore, Songdo or Hyderabad and the change i...

 July 13, 2026 | Analysis

APAC's Peptide-Capacity Gamble

For most of pharmaceutical history, the hard part was finding a molecule that worked. The GLP-1 class inverted that logic. The science arrived first &mdash...

 July 09, 2026 | Analysis

Singapore Updates Wegovy Label to Include Higher-Dose Semaglutide Data Showing Up to 25% Weight Loss

Up to one in three participants on semaglutide 7.2 mg achieved at least 25% weight loss over 72 weeks Mean weight loss with semaglutide 7.2 mg reached 2...

 July 09, 2026 | News

After the Rush: APAC's mRNA and Vaccine Capacity Hangover

In June 2022,  South Korea had something it had wanted for two years: a COVID-19 vaccine of its own. SKYCovione, developed by SK bioscience with the U...

 July 08, 2026 | Analysis

The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?

In Songdo and Bengaluru, the numbers finally look like the ones the region was promised a decade ago. Celltrion closed 2025 with revenue above ₩4 trillio...

 July 07, 2026 | Analysis

The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?

The requirement: a chain that cannot break Key figures −150°C or colder — the temperature floor for most cell and gene therapies; som...

 July 06, 2026 | Analysis


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close